Janson Pharmaceuticals Incurred the following costs In 2018 related to a new cancer drug: Research for new formulas Development of a new formula Legal and filing fees for a patent for the new formula $ 2,435,8e 1,61e,8ee 61,888 $ 4,186,808 Total The development costs were Incurred after technological and commercial feasibillty was established and after the future economic benefits were deemed probable. The project was successfully completed and the new drug was patented before the end of the 2018 fiscal year. Required 1. Calculate the amount of research and development expense Janson should report In its 2018 Income statement related to this 2. Calculate the amount of research and development expense Janson should report In its 2018 Income statement related to this project. Assuming that Janson prepares its financial statements according to International Financial Reporting Standards. 1 Research and development expense 2 Research and development expense